I found this a really useful article. They use RMD as the example but lessons applicable to any company

Best

C

How to identify a company's capital allocation strategy

ResMed is used as an example of how to spot a company’s capital allocation strategy in its financial statements.

Joseph Taylor

Capital allocation is the act of deciding what to do with cash generated from operations or raised from equity or debt markets. It is often referred to as a CEO’s most important job, and they generally have five main options.

The five main avenues for capital

Pay dividends

Dividends are perhaps the purest form of capital return. The company decides a percentage of profits to pay out and each shareholder gets a cash payment for each share they own. The shareholder can then decide to spend, save or reinvest the funds they receive.

Buy back shares

By buying back shares the company increases the percentage ownership of the remaining shareholders. Just like any share purchase, price matters. If shares are repurchased at a price above their intrinsic value, it is likely the money could have achieved a better return elsewhere.

Pay down debt

Paying off debt is also a return of capital – only this time to bondholders rather than shareholders. This can also be a good thing for shareholders as lowering debt can reduce the financial risk of a company. It should also reduce future interest and debt payments, meaning more cash can be allocated elsewhere.

Invest in organic growth

Profits can be reinvested in the hope of sowing even more profits in the future. Investments in organic growth might include buying more property and equipment, increasing research and development spending, hiring more staff or moving into new territories or product lines.

Buy other companies

Instead of reinvesting internally, management might choose to acquire another company. Creating shareholder value through acquisitions is famously hard – but it is possible. Berkshire Hathaway (NYS:BRK.A), Constellation Software and Danaher (NYS:DHR) have excelled while channeling a lot of capital towards acquisitions. But the fact they are so famous might tell you something.

Unless investments in growth can return more than the company’s cost of capital, profits should likely be put towards dividends, debt reduction and share buybacks at favourable prices. The right decision for a company is closely linked to the maturity of its business and the industry it operates in. If a company still has plenty of room to grow its sales and profits, a higher reinvestment rate is probably more suitable.

How to spot capital allocation decisions in the financial statements

This article will show you how to assess capital allocation decisions in a company’s numbers. To do this, we will study ResMed’s income statement, cash flow statement and balance sheet from their 2016-2023 annual reports.

ResMed (ASX:RMD) is a medical device and software company focused on treating sleep apnea. They are one of two leading players in the market and recorded over USD $4 billion of revenue in 2023. Because ResMed’s primary market listing is in New York, the numbers in this article are all in US dollars.

First, we’re going to look at how much of ResMed’s profits have been dedicated to returning capital versus growth investments. To do that, we’re going to look at dividends and share buybacks.

ResMed's dividend payout ratio

To find out what percentage of ResMed’s 2023 profits were paid out as dividends, I took the “Cash Dividends Paid” from the financing section of their Cash Flow Statement. I then divided this number by “Net Income” figure at the top of this document. You can see both of these numbers highlighted in the cash flow statement below. 

ResMed earned $0.9 billion in profit in 2023 and paid out around USD 0.25 billion of it in dividends.

This gives us a dividend payout ratio of 29%, which is relatively low compared to other large-cap ASX stocks and other healthcare firms:

A lower dividend payout ratio can mean that management sees opportunities to invest profitably in future growth. By contrast, more mature companies in low growth industries usually pay out most of their profits as dividends.

Like most financial measures, dividend payout ratios are more useful when you look at them over a longer period. Doing so shows us that ResMed’s dividend payout ratio has trended down from over 50% to around 30%.

Even at this early stage, we’ve learned two valuable things about ResMed’s capital allocation:

• It has a relatively low dividend payout ratio
• 
  
• It has recently pivoted to paying a lower percentage of profits out as dividends

I then looked at share buybacks to see if ResMed’s profits have been funneled here instead.

ResMed's share buybacks

Share buybacks show up in the investing activities section of the Cash Flow statement under the line item “Payments for common stock”. At the time of their 2023 annual report, ResMed had not spent any money on share repurchases since 2019 so there is no line entry for this in the 2023 report. 

The Cash Flow Statement does show us the money generated by issuing new shares. For ResMed, this has been larger – a total of over $300m since 2016. You might want to understand why this has happened, but it is beyond our remit today. One thing is clear though – ResMed has not used its profits to aggressively reduce the share count recently.

Let’s look at our running total:

• ResMed has a relatively low dividend payout ratio
• 
  
• ResMed pivoted to paying out less profits
• 
  
• ResMed is not buying back shares at the moment

This suggests that most of ResMed’s profits are being reinvested in the hope of generating future profits.

Different types of growth investment

As we covered earlier, growth investments can be organic (internal) or inorganic (buying other companies). Investments in organic growth might include:

• Higher research and development (R&D) spend
• 
  
• Hiring more staff
• 
  
• Buying more Plant, Property and Equipment (usually called Capital Expenditures or capex)

For investments in R&D and capex, it can be useful to take these amounts as a percentage of a company’s revenue over time. To do this, I found the amount spent on R&D near the top of ResMed’s Income Statement:

And I found their outlay on capex in the “Cash flow from investing activities” part of the Cash Flow Statement:

Taking a longer view, we can see that both R&D and Capex have stayed at similar levels as a percentage of revenue:

Staff are another potential investment area, so I looked at the number of full-time employees reported in ResMed’s annual reports:

ResMed’s headcount has essentially doubled since 2018. But this hasn’t happened in a straight line. There are several years of small growth and a few big bumps in 2016, 2017, 2019 and 2023. This offers a clue as to how ResMed has invested in future growth.

ResMed’s acquisition strategy

By looking at the investing activities section of ResMed’s cash flow statement since 2016, we can see they have spent over $3 billion buying other businesses. The company’s net income totaled just under $4.2 billion over this period, so it is a significant amount.

As we suspected from the changes in headcount, ResMed’s biggest dealmaking years were in 2016, 2019, and 2023. Here is how Morningstar analyst Shane Ponraj describes ResMed’s acquisition strategy:

“ResMed has made acquisitions of home healthcare software platforms as it seeks to leverage the trends of digital health and providing care in a lower-cost setting. Brightree, acquired in 2016, and MatrixCare, acquired in 2019, offer business management software for a range of home health providers. ResMed is currently directing significant capital to this area, and although high returns have largely been unproven, we think the move has been strategically sound given the structural industry tailwinds.

ResMed also has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery needed, ResMed’s minority stake hedges some risk from emerging competition.”

As Shane alluded to, it can be hard to judge the merit of an acquisition until many years later. But we can be clear on this: ResMed has allocated a lot of capital to acquisitions over the past few years.

Another important use of capital

You might remember that paying off debt is another common way to spend excess profits. You can see repayments of debt in the financing section of a company’s cash flow statement:

The effects of this will also show up in the balance sheet, which shows what a company owns (assets) and owes (liabilities). Major things to note in the balance sheet include:

• Total borrowings (the sum of current and long-term debt)
• 
  
• Cash and equivalents (from the balance sheet)
• 
  
• Net debt (borrowings minus cash)

Here is that data for ResMed from 2016-2023:

I have highlighted ResMed’s big dealmaking years in yellow because I think there is clear trend. Whenever ResMed has borrowed money to do a deal, it has aggressively channeled earnings towards debt repayments in the years after.

Total borrowings fell from almost $1.2bn in 2016 to $0.3bn in 2018. Then they fell again from almost $1.3bn in 2019 to under $0.7bn in 2021. This shows how knowledge of real-world events adds context to the numbers you see bouncing around in financial statements.

What we’ve learned about ResMed

ResMed’s financial statements have taught us a lot about their capital allocation in recent years. We learned that:

• ResMed has cut the percentage of profits distributed as dividends
• 
  
• ResMed did not buy back a lot of its own shares
• 
  
• ResMed’s investments in R&D and Capex stayed constant
• 
  
• ResMed allocated most capital to acquisitions and paying off debt

One thing we haven’t done is assess how wise these capital allocation decisions were.

That is a topic for another day – but in case you were curious, our analyst Shane Ponraj rated ResMed’s capital allocation as “Exemplary” as of May 2024. He cited a strong balance sheet, efficient investments and appropriate shareholder distributions.

If you'd like to learn more about assessing capital allocation, take a look at Shani's article 'The most important decision a CEO can make'.

And for more on ResMed, you can view its security detail page here and read about their impressive Q3 fiscal 2024 earnings here.

Nothing particularly new in this report but some numbers and assumptions with which to compare to.

ResMed’s impressive earnings

Strong device sales and rebound in margin.

Shane Ponraj

Shares in narrow-moat ResMed (ASX: RMD) remain undervalued following a strong third-quarter fiscal 2024. Underlying earnings before interest and taxes (“EBIT”) of USD 394 million was 8% higher than second-quarter fiscal 2024, with sales up 3% and the underlying EBIT margin expanding 145 basis points to 33%.

Sales growth was largely driven by new patient demand while gross margins expanded significantly due to reduced freight and manufacturing cost improvements. Given the quicker-than-expected margin improvement, we increase our fiscal 2024 underlying EBIT forecast by 5% to USD 1.47 billion. Our long-term earnings estimates increase more modestly by roughly 2%. We raise our fair value estimate by 2% to USD 264, or $40 per CDI (ASX listed shares) at current exchange rates.

Improving patient flow and availability of devices continues to support strong sales. We also anticipate further margin expansion as ResMed’s sales mix shifts to higher-margin masks, and cost inefficiencies of simultaneously producing its older AirSense 10 device cease. Our midcycle 34% EBIT margin forecast is broadly unchanged.

Our forecast five-year revenue compound annual growth rate increases to 10% from 9% prior. The global sleep apnea market remains largely untapped and more than big enough for ResMed to remain a meaningful part of the solution. A key trend we think is helping boost new patient diagnoses is wearable technology such as the Apple Watch that can track and indicate signs of sleep disorder breathing.

There continues to be no negative impact from GLP-1 drugs. ResMed has gathered data on 660,000 patients who have been prescribed a GLP-1 drug and have a sleep apnea diagnosis. It was found that participation rates for positive airway pressure therapy were 10.5 percentage points higher in the sample population versus patients who have not been prescribed a GLP-1 drug. In addition, mask resupply rates in the sample population were 3.1 percentage points higher one year after the PAP setup and 5.0 percentage points higher two years after the PAP setup.

Business strategy and outlook

ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. 

With cloud-connected devices, physicians can monitor patient compliance and encourage continued use. Higher adherence supports both reimbursement rates from payers and the resupply of masks and accessories.

ResMed also plays a key role in producing clinical data that demonstrates treatment can minimize related risks such as hypertension, stroke, heart attack and Alzheimer’s disease. Through its own testing devices and education, ResMed seeks more widespread diagnosis and treatment of OSA.

The global OSA homecare device market, is a two-player duopoly with over 80% estimated market share split between ResMed and Philips, with ResMed the market leader in the majority of the 140 countries it competes in.

The market offers a large global growth opportunity as penetration within developed markets is estimated at one fifth of the roughly 15% prevalence, and emerging markets are essentially untapped. In the US, we estimate roughly half of the 22 million people diagnosed with OSA are treated with continuous positive airway pressure, or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for growth.

ResMed has made acquisitions of home healthcare software platforms as it seeks to leverage the trends of digital health and providing care in a lower-cost setting. Brightree, acquired in 2016, and MatrixCare, acquired in 2019, offer business management software for a range of home health providers. ResMed is currently directing significant capital to this area, and although high returns have largely been unproven, we think the move has been strategically sound given the structural industry tailwinds.

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery needed, ResMed’s minority stake hedges some risk from emerging competition.

Moat rating

Learn more about how to identify companies with sustainable competitive advantages.

We award ResMed a narrow moat rating based on switching costs and intangible assets, which have helped the company achieve high customer adherence rates and above-average industry growth.

In fiscal 2020, both ResMed and Philips reported selling over 10 million total cloud-connectable medical devices globally to date. In fiscal 2021, ResMed crossed the 15 million mark. These newer-generation devices enable physicians to remotely monitor the patient’s usage and breathing performance, entrenching ResMed as a preferred provider with all three users of the data.

For the patient, the device feedback encourages usage and allows them to get individualized care from the physician, leading to better clinical outcomes. For the physician, trust in recorded data and grown familiarity with the software is likely to reduce switching to a different provider.

For the payor, evidence of patient compliance informs continued reimbursement support. The duopolistic nature of the market is also in the best interest of durable medical equipment, or DME, suppliers as it limits the number of device manufacturers they deal with.

These factors have contributed to ResMed reporting up to 87% adherence rates when the physician is using its cloud-based patient monitoring system, AirView, compared with the estimated industry average adherence rate of 50%. A higher adherence rate benefits both device upgrades as well as masks and accessories revenue as the physician reminds the patient of when they should be replaced.

ResMed typically earns 40% of group revenue from the resupply of masks and accessories. Although these are interchangeable with other brands, competitors would be challenged to offer original products that are comparable in quality and comfort without infringing on ResMed’s plethora of patents, while also having to compete with its entrenched relationships.

ResMed’s intangible assets, namely its brand and patent portfolio, have also contributed to above-average industry growth and helped maintain its commanding market share. ResMed typically spends roughly 7% of revenue on research and development each year, which has ensured consistent product launches.

Despite growing off a much smaller base, Fisher & Paykel’s competing homecare segment has a trailing five-year revenue CAGR of 5%, lagging ResMed’s 10% over the same period. We think ResMed’s intangible brand has also enabled significant price premiums over less well-known peers.

While Philips and ResMed are comparatively priced, we estimate ResMed’s pricing to be roughly 15% higher than the remaining peer average across the automatic positive airway pressure device category and 30% higher in the CPAP category. This may reflect higher reimbursement support. In addition, we think ResMed’s patent portfolio of over 8,200 granted or pending patents, will likely assist ResMed in maintaining its market share with less than one third expiring in the next five years.

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We anticipate the company’s ROIC to far exceed its weighted cost of capital of 7.4% over our explicit forecast period, even in our bear-case scenario.

Phillips is settling in the US for personal injury caused by its faulty sleep apnoea devices.

The market is loving it, with shares up big. ResMed is down mildly in the pre-market.

More here - https://www.cnbc.com/2024/04/29/philips-shares-rocket-33percent-as-firm-settles-us-respiratory-device-case.html

Strong results, revenue, earnings, gross margin, patient numbers up. "double-digit growth in both operating profit and earnings per share,” - Shredding the bear case and shorters last year so far.

Should be a strong day today - up high single digits in the US afterhours.

Third Quarter 2024 Highlights

All comparisons are to the prior year period

• Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis 
• Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew 240 bps to 58.5%
• Income from operations increased 25%; non-GAAP operating profit up 23%
• Operating cash flow of $402 million and debt repayments of $220 million
• Diluted earnings per share of $2.04; non-GAAP diluted earnings per share of $2.13

https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds

RMD had a 5% drop in the US overnight after Eli Lilly’s SURMOUNT phase 2 result.

Looking at the results from a pleb’s point of view.

1. Looks huge. A ~27 drop in events per hour. RMD ded.
2. But they didn’t explicitly disclose where the patient's AHI started and where they ended. Looks like might be something like from 50 to 25 events. Which still makes them moderate OSA patients. Still need PAP therapy.
3. Patients using PAP with the drug performed slightly better. So a RMD baggy would say that it’s in fact a tailwind because Lilly will help led gen for RMD.

Interested to hear what others think

The shares seem to have broken out of a multi-month range between $21-25, on reasonable volume, which is encouraging price action. If this holds, a trip north of $30 beckons (likely hastened by the next quarterly earnings report on 24/01 if it beats expectations).

DreamStation 2 safety warning could delay Philips returning to the market 

On 28 Nov 2023, the FDA issued a safety communication warning to users of Philips' Dreamstation 2 devices that their devices could overheat. The FDA has received 270 Medical Device Reports (MDRs) between 1 Aug 2023 and 15 Nov 2023 of thermal issues such as fire, smoke, burns and other signs of overheating (vs 30 MDRs in the previous 3 years)

From RBC Capital Markets:

We believe this issue for Philips' CPAP devices could further delay the finalisation of its Consent Decree and therefore lead to an extension of its time out of the new patient market in the US. We currently assume Philips returns to the Americas new patient market during the Sep 24 qtr, and therefore any delay to the finalisation of Philips’ Consent Decree could lead to higher devices sales for RMD. This new overheating issue for DreamStation 2 devices may also impact Philips' sales to new patients in markets outside the US, which could also lead to higher device sales for RMD in RoW markets 

DISC: Held in SM & RL

Unsure what if any the practical implications of this are yet ...

ResMed has issued an urgent field safety notice for certain models of its AirFit masks that contain magnets, citing issues around interference with medical implants. In a letter sent to patients on 20 November, the US-headquartered company updated the contraindications and warnings in the user guides for the masks. The masks affected include multiple AirFit models from its full-face mask, nasal mask, and non-vented mask ranges and are used to deliver air from a positive airway pressure (PAP) device

The masks use magnets to provide easier attachment and detachment to headgear. The company says their use is especially important to patients with dexterity vision impairment, or those with disabilities. The safety notice is due to reports of magnetic interference of the magnets with implanted devices in the patient. ResMed has submitted five reports of serious harm, potentially caused by this issue, to regulatory authorities. No deaths have been reported. ResMed said that medical device function could be affected, whilst ferromagnetic implants could change position because of mask magnet proximity. Active medical implants that could be affected include cardiovascular devices such as pacemakers, and implantable cardioverter defibrillators (ICD). Neurostimulators and cerebrospinal fluid (CSF) shunts can also suffer from interference, along with diabetes devices such as insulin/infusion pumps. ResMed also stated that patients with metallic implants containing ferromagnetic materials are contraindicated for using the masks. This includes, among others, patients with stents, valves, and flow disruption devices. ResMed warned users to keep the mask magnets at least six inches away from medical devices or implants that may be affected. According to the letter, ResMed has sold tens of millions of masks across the last nine years

ResMed is not the only company to run into problems with magnetic masks. Philips, which has battled large recalls across its respiratory medical devices, alerted customers to safety issues of its continuous PAP or bi-Level PAP therapy masks after reports similarly designed magnets were affecting implanted devices. The US Food and Drug Administration (FDA) tagged Philips' recall as Class I, the most serious classification. The recall involved over 18 million devices sold in the US

DISC: Small position Held in RL & SM

ResMed has announced a host of leadership changes as "part of a new operating model to accelerate long-term growth"

Chief among the executive changes is the retirement of Rob Douglas, current president and chief operating officer, on January 1, 2024. Other moves include the appointment of Justin Leong as chief product officer, Katrin Pucknat as chief marketing officer and Mike Fliss as chief revenue officer. All changes are effective immediately

"The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team. This change aims to increase the velocity of product development and sharpen our customer and brand focus", RMD said in a statement

The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team. This change aims to increase the velocity of product development and sharpen our customer and brand focus. Ultimately, the goal is to accelerate profitable growth, while driving greater value and improved care throughout the outside hospital care continuum and the patient journey

ResMed’s new Product-led, Customer-centric, and Brand-enhanced operating model includes the following executive leadership team:

Leaders appointed into new roles:

• Chief Product Officer – Justin Leong (previously president, Asia and Latin America)
• Chief Marketing Officer – Katrin Pucknat (previously president, Germany)
• Chief Revenue Officer – Mike Fliss (previously vice president, North America sales)

In addition to the above roles, the executive leadership team also includes:

• Chief Commercial Officer, SaaS – Bobby Ghoshal
• Chief Financial Officer – Brett Sandercock
• Chief Legal Officer – Mike Rider
• Chief People Officer – Vered Keisar
• Chief Strategy Officer – Hemanth Reddy

The extended CEO operations team, reporting directly to the CEO, includes:

• Chief Compliance Officer – Jim Ellis
• Chief Information Security Officer – Todd Friedman
• Chief Investor Relations Officer – Amy Wakeham
• Chief Medical Officer – Carlos Nunez
• Chief Quality & Regulatory Officer – Dawn Haake
• Chief Supply Chain Officer – Andrew Price

ResMed also announced that Rob Douglas, current president and chief operating officer, plans to retire on January 1, 2024. Rob will immediately transition from his current role to a new role as special advisor to the CEO and remain in a consulting role through December 31, 2024. Additionally, Lucile Blaise, current president sleep and respiratory care, will immediately transition to a new role as senior vice president, strategy & business development, reporting to Hemanth Reddy. Finally, as part of the operating model evolution, the digital health technology product organization will now report to Justin Leong, and Urvashi Tyagi, current chief technology officer, will immediately transition to a role as special advisor to the Chief Product Officer through January 1, 2024. Urvashi will remain in a consulting role through December 31, 2024

usually dont get too intersted in quarterlies, but this one did hold some interest. Re GLP-1, RMD seeing no impact across various cohorts, possibly some uptick. Mask sales are strong, and adherence remains strong, which is an indicator of repeat ordering. then i noticed the below...

blue is non GAAP and orange GAAP GM's. still enough to get bears excited i would say in this environment. interesting diversion probably adds to anxiety. RMD spoke to better trend expected through the year says decline mainly higher component costs that are starting to be cycled. we will see

the rest looked good to me.

disc Held

Channeling the spirit of "Strawman" I'll float a bear case for Resmed. So much has been written that the share price drop isn't justified based on the new weight loss drugs. But maybe Resmed was just overvalued before? At current price we're looking at 20-25 PE for a mature company that will do well to grow around 10% a year. I'd say a company growing around 10% is worth a PE around 20. So even if Ozempic doesn't dent Resmed's growth, I still don't see huge value at current share price for Resmed.